2,714 Shares in Astrazeneca Plc $AZN Purchased by Founders Grove Wealth Partners LLC

Founders Grove Wealth Partners LLC purchased a new stake in Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,714 shares of the company’s stock, valued at approximately $249,000.

Several other large investors have also recently bought and sold shares of the stock. Triumph Capital Management acquired a new position in shares of Astrazeneca in the third quarter valued at approximately $25,000. Rakuten Investment Management Inc. bought a new position in shares of Astrazeneca during the third quarter worth approximately $31,000. JPL Wealth Management LLC acquired a new stake in Astrazeneca during the 3rd quarter worth approximately $35,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in Astrazeneca by 144.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after purchasing an additional 275 shares during the last quarter. Finally, Aventura Private Wealth LLC bought a new stake in Astrazeneca in the 4th quarter valued at $46,000. 20.35% of the stock is owned by institutional investors.

Astrazeneca Stock Performance

Astrazeneca stock opened at $185.54 on Wednesday. Astrazeneca Plc has a one year low of $122.48 and a one year high of $212.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94. The firm has a market cap of $287.75 billion, a price-to-earnings ratio of 31.96, a P/E/G ratio of 1.39 and a beta of 0.32.

Astrazeneca Dividend Announcement

The business also recently declared a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were given a $1.595 dividend. The ex-dividend date was Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s dividend payout ratio (DPR) is presently 74.83%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on AZN shares. Citigroup began coverage on Astrazeneca in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Friday, February 6th. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Friday, March 20th. Guggenheim reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, December 3rd. Finally, TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $95.75.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.